Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 3/20 | 0.50 |
| ▸ | AKT1 | P31749 | 1/20 | 0.50 |
| ▸ | ILK | Q13418 | 1/20 | 0.49 |
| ▸ | LATS1 | O95835 | 8/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | LATS2 | Q9NRM7 | 4/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.35 |
| ▸ | CLK2 | P49760 | 2/20 | 0.35 |
| ▸ | HIPK1 | Q86Z02 | 2/20 | 0.35 |
| ▸ | HIPK2 | Q9H2X6 | 2/20 | 0.35 |
| ▸ | HIPK3 | Q9H422 | 2/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.35 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CLK1 | P49759 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18024850 | 0.76 | AKT2 (0.52) | AKT2AKT1ILKROCK2MAPK1 | |
| SCHEMBL29887199 | 0.74 | NPC1 (0.59) | PDPK1MAPK1MAPT | |
| SCHEMBL2851617 | 0.74 | NPC1 (0.59) | PDPK1MAPK1MAPT | |
| SCHEMBL5211835 | 0.71 | MAPK1 (0.59) | AKT2AKT1ILKMAPK1MAPT | |
| SCHEMBL29590784 | 0.71 | MAPK1 (0.59) | AKT2AKT1ILKMAPK1MAPT | |
| SCHEMBL5112063 | 0.71 | ILK (0.42) | AKT2AKT1ILKLATS1ROCK2 | |
| SCHEMBL29077582 | 0.70 | AKT2 (0.48) | AKT2AKT1ILKROCK2MAPK1 | |
| SCHEMBL30616953 | 0.70 | AKT2 (0.48) | AKT2AKT1ILKMAPK1MAPT | |
| SCHEMBL30616902 | 0.70 | AKT2 (0.48) | AKT2AKT1ILKROCK2MAPK1 | |
| SCHEMBL27091366 | 0.70 | AKT2 (0.48) | AKT2AKT1ILKMAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234276-A1 | Heterocyclic Triazines as Hypoxic Selective Protein Kinase Inhibitors | SENTINEL ONCOLOGY LIMITED (UK) | 2008-09-25 | — | — | US | claimed |
| EP-1846392-A2 | HETEROCYCLIC TRIAZINES AS HYPOXIC SELECTIVE PROTEIN KINASE INHIBITORS | Sentinel Oncology Limited (GB) | 2007-10-24 | — | — | EP | claimed |
| WO-2006131835-A2 | HETEROCYCLIC TRIAZINES AS HYPOXIC SELECTIVE PROTEIN KINASE INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2006-12-14 | — | — | WO | claimed |
| US-20080234276-A1 | Heterocyclic Triazines as Hypoxic Selective Protein Kinase Inhibitors | SENTINEL ONCOLOGY LIMITED (UK) | 2008-09-25 | — | — | US | disclosed |
| EP-1846392-A2 | HETEROCYCLIC TRIAZINES AS HYPOXIC SELECTIVE PROTEIN KINASE INHIBITORS | Sentinel Oncology Limited (GB) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006131835-A2 | HETEROCYCLIC TRIAZINES AS HYPOXIC SELECTIVE PROTEIN KINASE INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234276-A1 | Heterocyclic Triazines as Hypoxic Selective Protein Kinase Inhibitors | HIF1AN, HIF1A, CDK2 | AKT2 295/4885AKT1 245/4885ILK 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.